NEW YORK, Aug. 31 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
The primary advantage of synthetic bone graft substitutes and growth factors compared with allograft bone tissue is that they do not depend on the availability of donated human tissue. In addition, owing to the potential risk of disease transmission, synthetic materials and growth factors may be perceived as safer than allograft-based bone tissue. Many new composite products are also becoming available which seek to harness the combined characteristics of synthetic and natural materials in one single product optimised for rapid bone repair and regeneration.
Stem cell therapy is also showing huge potential as an alternative to autograft. Mesenchymal stem cells (MSCs) found in bone marrow, can form a variety of cells in the laboratory, including fat cells, cartilage, bone, tendon and ligaments, muscles cells, skin cells and even nerve cells. Unlike most other human adult stem cells, MSCs can be obtained in quantities appropriate for clinical applications, making them good candidates for use in tissue repair. They also offer the advantage of low morbidity and cost.
The last twelve months has seen consolidation in the orthobiologic sector, although most of the acquisitions have been relatively small in terms of money. The largest acquisition, and of particular interest, is the rather surprising entry into the segment of negative-pressure woundcare company, Kinetic Concepts, with its proposed acquisition of LifeCell, a leading provider of biological products for soft tissue repair, for US$1.7 billion.
The emergence of gene therapy?
Gene therapy has the potential to provide the ideal solution for treating a variety of musculoskeletal disorders. The promise of gene therapy is the ability to efficiently transfer new genetic material into patient cells to either replace defective genes or introduce therapeutic genes in order to treat disease.
To date, much of the research in gene therapy for the enhancement of spine fusion has centred on the transfer of genes-encoding BMPs and related proteins. Recombinant, osteogenic growth factors are now available to enhance bone repair, particularly in those applications related to the treatment of fracture non-unions and the enhancement of fusion of the spine. However, there is concern that a single dose of an exogenous protein will not induce an adequate osteogenic signal in many patients, particularly in those cases where there is a compromise of host bone and the surrounding soft tissue.
What will the value of stem cell therapies be in 2012?
What are the market growth drivers for the allograft tissue market?
What are the advantages and disadvantages of platelet-derived growth factors?
The synthetic bone graft market was estimated to be worth US$250 million in 2007. By what annual rate is it expected to grow over the next 5 years?
Who are the companies with novel technology in the soft tissue repair area?
What is DePuy's product line-up in the orthobiologics sector?
What is Genzyme's interest in China?
With which Australian company did Smith & Nephew sign a distribution deal in March 2008?
To understand the market and the leading companies that are driving growth and innovation you need this report
The Global Market for Orthobiologics:
Players, products and technologies driving change
Volume I of the report looks more closely at the issues and markets as a whole and focuses on current and novel development in the following key sectors:
Demineralised Bone Matrix
Synthetic Bone Graft
Stem Cell Therapy
Joint Fluid Therapy
Market estimates for orthobiologics materials vary greatly because the orthobiologics market is not clearly defined. Some estimates include only bone substitute materials, whereas this report also includes hyaluronic acid injections for joint fluid therapy and articular cartilage repair products.
The global orthobiologics market was estimated by Espicom to be worth US$4.2 billion in 2007 and accounted for 13% of the US$33 billion total orthopaedic market. With an annual growth rate of 17%, orthobiologics is the fastest growing orthopaedic segment.
The global orthobiologics market is projected to almost double by 2012, driven by technological advances and an ageing, increasingly active population giving rise to more people aged over 60 diagnosed with musculoskeletal conditions. Stem-cell therapies are forecast to be the fastest-growing category, with a CAGR of 53.9% over the next five years.
Volume II of the report provides extensive company information on over 50 leading companies focusing on:
Who's Working with Whom?
While the large multinationals have a significant presence, the orthobiologics segment is very fragmented and is mainly inhabited by much smaller companies, many of which have products that are only in the early stages of development. The orthobiologics market is currently led by Medtronic which has an expanding orthobiologics portfolio, the lead product of which is the company's InFUSE Bone Graft, which dominates the bone morphogenic protein market with an over 90% market share.
To illustrate the corporate rationalisation of the market, in November 2007 Regeneration Technologies, Inc. (RTI), a leading processor of orthopaedic and other biologic implants, and Tutogen Medical, a leading manufacturer of sterile biological implants made from human (allograft) and animal (xenograft) tissue, announced a definitive agreement to combine the two companies in a tax-free, stock-for-stock exchange valued at US$205 million.
Among the companies covered in the report
Allograft Tissue Systems Inc (ATSI)
Berkeley Advanced Biomaterials
Fidia Advanced Biopolymers
Nanocoatings Pty Ltd
Smith & Nephew
Table of Contents available upon request
To order this report:
Intl: +1 805-652-2626